This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Omeros’s 8K filing here.
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Read More
- Five stocks we like better than Omeros
- Top Stocks Investing in 5G Technology
- Should You Hold Nvidia Stock for the Long Haul or Trade It?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
